ERBB2 and cancer: Finally, recent advances in the area of cancer immunotherapy have shown that tumors with tumor infiltrating lymphocytes (TILs) have a higher pathological complete response (pCR) rate in the neoadjuvant setting, especially in TNBC and HER2+ cancers,16–19 suggesting that immunologically active tumors are more likely to achieve an optimal clinical response to anti-cancer therapies.